Top member reports
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Bull Case
stale
Still has massive potential for continued growth - Global player not restricted by limitations of Austalian market.
Revenues spread across Nth American market, Europe, Aus, Asia + ROW
Falling A$ will improve future earnings
5th Largest Global Biotech
- Revenues ~$8bn into more than 60 countries
- Major capacity expansion underway
- R&D investment $702m
- Deep R&D pipeline fueling future growth
Risks: Competitive product launches, plasma donor fee inflation, regulatory pressures (notably China), potential CSL112 trial failure
